Charles River Laboratories Is Well-Positioned For 2019, So Just Stay Long

Summary:

- Charles River Laboratories recently reported Q3 2018 results that beat the top- and bottom-line estimates and management increased their full-year 2018 guidance.

- Charles River is well-positioned for 2019, so I believe that this small-cap company is worthy of investment dollars.

- I am long CRL shares, and I may get longer in the near future.

Charles River Laboratories ($CRL) is a company that does not get much attention, but if you ask me, this will change in the years ahead. This drug discovery and early-stage development company has a great story to tell, and I believe that the strong stock performance seen so far in 2018 will likely continue over at least the next 12 months.

Investors should not think that they missed the boat on CRL shares due to the significant outperformance, but instead, now may actually turn out to be a great long-term buying opportunity because I believe that Charles River is well-positioned for 2019 and beyond.